Drug intelligence / Profile preview

IsoNAP

Development stage: Preclinical
Modality: Peptides
Administration: Oral, Intramuscular, Intravenous

Overview

IsoNAP is a novel peptide analog of NAP (davunetide) designed to enhance β-sheet breaker characteristics. This modification involves the replacement of proline residues with alpha-aminoisobutyric acid, aiming to reduce protein misfolding. Preclinical studies have demonstrated that IsoNAP protects neurons against amyloid beta (1-42) toxicity, inhibits the aggregation of tau-derived peptides, and safeguards cognitive functions in models of activity-dependent neuroprotective protein (ADNP) deficiency. Its mechanism of action focuses on neuroprotection and reducing tau pathology, making it of interest for conditions like Alzheimer's disease.

Other names: NAP alpha-aminoisobutyric acid

Targets

Tau aggregates (Microtubule-associated protein tau (pathological form))Misfolded and aggregating proteinsAmyloid-beta aggregate (N-terminal epitope)

Beyond the preview

Go deeper on IsoNAP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IsoNAP.

Explore the full profile